Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
ASH Multiple Myeloma
CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.
Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.
Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.
Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.
Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.
Adding daratumumab to either of two standard-of-care treatment regimens induces rapid, deep, and durable responses and improves progression-free survival in patients with relapsed/refractory multiple myeloma, confirm updated findings from the open-label phase III POLLUX and CASTOR trials.
An investigational antibody-drug conjugate that targets a key B-cell maturation antigen, offers “deep and durable” responses to some patients with relapsed/refractory multiple myeloma, suggest preliminary findings from the expansion part of the phase I DREAMM-1 trial.
The 4-year overall survival rate is 82.3% among multiple myeloma patients eligible for autologous stem cell transplantation, according to a retrospective study.